BioVaxys Technology Corp.

Recent News

  • BioVaxys Announces Closing of Financing

    Vancouver, British Columbia--(Newsfile Corp. - February 5, 2021) - BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or the "Company"), is pleased to announce that it has closed its previously announced non-brokered private placement (the "Private Placement").Under the Private Placement, the Company has issued 4,417,647 units ("Units") at a price of $0.255 per Unit to certain strategic investors for total gross proceeds of approximately $1,126,500. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant...

    2021-02-05 7:00 AM EST
  • BioVaxys Announces Investment by Strategic Investor

    Vancouver, British Columbia--(Newsfile Corp. - February 1, 2021) - BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or the "Company"), is pleased to announce a non-brokered private placement (the "Private Placement") consisting of 4,313,725 units ("Units") at a price of $0.255 per Unit for total gross proceeds of approximately $1,100,000. The Private Placement has been fully subscribed by one strategic investor. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant")....

    2021-02-01 2:30 PM EST
  • BioVaxys Announces Form 211 Clearance For OTC Trading in the USA

    Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that its submission of Form 211 to FINRA has been cleared and the Company's shares now qualify for trading in the United States on the OTC Pink Market under the symbol "LMNGF". The Company has also made an application for its common shares to be DTC eligible and expects to receive this designation within the next...

    2020-12-10 8:00 AM EST
  • BioVaxys Provides Viral Vaccine Platform Program Update

    Vancouver, British Columbia--(Newsfile Corp. - November 30, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract....

    2020-11-30 8:00 AM EST
  • BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine

    Vancouver, British Columbia--(Newsfile Corp. - November 11, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. Previous interim data from the study showed it possessed an excellent emerging tolerability profile with no noteworthy clinical observations or observed toxicities in...

    2020-11-11 3:30 AM EST
  • BioVaxys Engages Advisor for Strategic Business Development

    Vancouver, British Columbia--(Newsfile Corp. - November 9, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has engaged Encounter Technology Limited ("Encounter"), a company controlled by one of its directors, Mr. David Wang, for the purpose of advancing the Company's strategic business objectives in Asia, including commercial partnerships, research collaborations, and other such transactions. Under the terms of the engagement, Encounter is entitled to various share payments triggered by...

    2020-11-09 8:00 AM EST
  • BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity

    Vancouver, British Columbia--(Newsfile Corp. - November 2, 2020) -  BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that...

    2020-11-02 8:00 AM EST
  • BioVaxys and The Ohio State University Enter into SARS-CoV-2 Research Collaboration to Study New Vaccine

    Vancouver, British Columbia--(Newsfile Corp. - October 26, 2020) - BioVaxys Technology Corp. (CSE: BIOV), is pleased to announce that it has entered into a research collaboration with The Ohio State University ("OSU") for BioVaxys' SARS-CoV-2 vaccine candidate. OSU is a leading global academic research institute in the fight against SARS-CoV-2, with The Ohio State University Wexner Medical Center ("OSUWMC") also recently selected as a site for SARS2 multicenter clinical trials.The objective of this research collaboration, which...

    2020-10-26 8:00 AM EDT